StockNews.com 开始报道 xBiotech（纳斯达克股票代码：XBIT）

StockNews.com began coverage on shares of XBiotech (NASDAQ:XBIT – Get Rating) in a report released on Tuesday. The brokerage issued a hold rating on the biopharmaceutical company's stock.

XBiotech Trading Up 3.7 %

XBIT opened at $3.61 on Tuesday. The company has a market cap of $109.88 million, a price-to-earnings ratio of -3.03 and a beta of 1.22. The company's 50 day moving average is $3.56 and its 200 day moving average is $3.58. XBiotech has a 12-month low of $3.00 and a 12-month high of $9.10.

Institutional Trading of XBiotech

Hedge funds and other institutional investors have recently modified their holdings of the company. Swiss National Bank raised its position in shares of XBiotech by 8.8% during the 1st quarter. Swiss National Bank now owns 46,800 shares of the biopharmaceutical company's stock valued at $404,000 after purchasing an additional 3,800 shares during the period. JPMorgan Chase & Co. raised its position in shares of XBiotech by 72.8% during the 1st quarter. JPMorgan Chase & Co. now owns 15,093 shares of the biopharmaceutical company's stock valued at $131,000 after purchasing an additional 6,360 shares during the period. Bank of New York Mellon Corp raised its position in shares of XBiotech by 32.0% during the 1st quarter. Bank of New York Mellon Corp now owns 78,874 shares of the biopharmaceutical company's stock valued at $681,000 after purchasing an additional 19,140 shares during the period. Dimensional Fund Advisors LP grew its position in shares of XBiotech by 50.8% during the first quarter. Dimensional Fund Advisors LP now owns 153,918 shares of the biopharmaceutical company's stock worth $1,330,000 after purchasing an additional 51,872 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of XBiotech by 15.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 44,693 shares of the biopharmaceutical company's stock worth $387,000 after purchasing an additional 6,085 shares in the last quarter. 10.06% of the stock is owned by hedge funds and other institutional investors.

XBiotech Company Profile

(Get Rating)

XBiotech, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Featured Stories

• Get a free copy of the StockNews.com research report on XBiotech (XBIT)
• Costco Sales Disappoint, Markets Are Missing This Upside Driver
• First Republic Bank Is A Speculative Play, Here's Why
• The WD-40 Company Bottoms With Reversal In Sight
• 3 Low-Cost Stock ETFs That Are Crushing It This Year
• FedEx Takes Flight; Analysts See More Gains Ahead

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.